Barclays Issues Positive Forecast for West Pharmaceutical Services (NYSE:WST) Stock Price

Key Points

• Barclays raised its target price for West Pharmaceutical Services from $265 to $275 and kept an "equal weight" rating, implying roughly a 2.68% upside from the prior close.
• West beat quarterly expectations with $2.04 EPS (vs. $1.83 est.) and $805M revenue (vs. $795.7M est.), and set FY2026 guidance of $7.85–$8.20 EPS while analysts' consensus for the current fiscal year is about $6.62.
• The Board approved a $1.00 billion stock buyback, authorizing repurchases of up to approximately 5.6% of outstanding shares.

West Pharmaceutical Services (NYSE:WST - Get Free Report) had its target price upped by equities researchers at Barclays from $265.00 to $275.00 in a research note issued on Tuesday,Benzinga reports. The firm presently has an "equal weight" rating on the medical instruments supplier's stock. Barclays's price target suggests a potential upside of 2.68% from the stock's previous close.

WST has been the topic of a number of other research reports. Wall Street Zen raised shares of West Pharmaceutical Services from a "hold" rating to a "buy" rating in a research note on Saturday, December 20th. Jefferies Financial Group reissued a "buy" rating and issued a $295.00 target price on shares of West Pharmaceutical Services in a research note on Tuesday, February 10th. Deutsche Bank Aktiengesellschaft reissued a "buy" rating and issued a $315.00 target price on shares of West Pharmaceutical Services in a research note on Friday, February 13th. UBS Group reissued a "buy" rating and issued a $340.00 target price on shares of West Pharmaceutical Services in a research note on Friday, February 13th. Finally, Weiss Ratings reissued a "hold (c)" rating on shares of West Pharmaceutical Services in a research note on Friday, January 9th. Three research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $315.67.

West Pharmaceutical Services Stock Up 3.0%

Shares of NYSE:WST traded up $7.87 during trading on Tuesday, reaching $267.83. 783,074 shares of the company traded hands, compared to its average volume of 963,692. The firm has a fifty day simple moving average of $246.34 and a 200 day simple moving average of $261.48. The firm has a market cap of $19.31 billion, a P/E ratio of 39.44, a price-to-earnings-growth ratio of 2.73 and a beta of 1.15. West Pharmaceutical Services has a 1-year low of $193.05 and a 1-year high of $322.34. The company has a quick ratio of 2.34, a current ratio of 3.02 and a debt-to-equity ratio of 0.06.

West Pharmaceutical Services (NYSE:WST - Get Free Report) last released its quarterly earnings data on Thursday, February 12th. The medical instruments supplier reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.83 by $0.21. The business had revenue of $805.00 million during the quarter, compared to analyst estimates of $795.70 million. West Pharmaceutical Services had a net margin of 16.06% and a return on equity of 17.90%. West Pharmaceutical Services's quarterly revenue was up 7.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.82 EPS. West Pharmaceutical Services has set its FY 2026 guidance at 7.850-8.200 EPS. Analysts anticipate that West Pharmaceutical Services will post 6.62 earnings per share for the current fiscal year.

West Pharmaceutical Services announced that its Board of Directors has approved a stock buyback plan on Tuesday, February 17th that permits the company to repurchase $1.00 billion in shares. This repurchase authorization permits the medical instruments supplier to reacquire up to 5.6% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company's board believes its shares are undervalued.

Institutional Investors Weigh In On West Pharmaceutical Services

Several large investors have recently bought and sold shares of WST. Elyxium Wealth LLC bought a new stake in shares of West Pharmaceutical Services during the fourth quarter worth $25,000. Bayban bought a new stake in shares of West Pharmaceutical Services during the fourth quarter worth $27,000. Private Trust Co. NA increased its position in shares of West Pharmaceutical Services by 156.4% during the fourth quarter. Private Trust Co. NA now owns 100 shares of the medical instruments supplier's stock worth $28,000 after acquiring an additional 61 shares in the last quarter. DV Equities LLC bought a new stake in shares of West Pharmaceutical Services during the fourth quarter worth $28,000. Finally, International Assets Investment Management LLC bought a new stake in shares of West Pharmaceutical Services during the fourth quarter worth $31,000. Institutional investors own 93.90% of the company's stock.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.